Abstract: An ultra-high sensitivity dual-gated biosensor based on an MOS transistor, which is applicable to detection of a series of early tumors. The sensor is prepared and processed by using SOI wafers, and a unique dual-gated structure is realized by ion implantation technique. The sensor is prepared by an ultraviolet lithography combined with an NLD etching method, realizing trace, instant and marker-free detection of tumor markers. The method detects a change in capacitance in the channel during binding of antigen antibodies. The detection method involved in the invention is more stable and strong in anti-interference, can meet the demands in the aspect of detection range and sensitivity, and especially has extremely outstanding detection sensitivity, and can detect a sample with a lowest concentration in the range of 1 fg/ml˜1 ng/ml.

Abstract: An ultra-high sensitivity dual-gated biosensor based on an MOS transistor, which is applicable to detection of a series of early tumors. The sensor is prepared and processed by using SOI wafers, and a unique dual-gated structure is realized by ion implantation technique. The sensor is prepared by an ultraviolet lithography combined with an NLD etching method, realizing trace, instant and marker-free detection of tumor markers. The method detects a change in capacitance in the channel during binding of antigen antibodies. The detection method involved in the invention is more stable and strong in anti-interference, can meet the demands in the aspect of detection range and sensitivity, and especially has extremely outstanding detection sensitivity, and can detect a sample with a lowest concentration in the range of 1 fg/ml˜1 ng/ml.

Abstract: Systems and methods for shading analysis and creating a 3D model of a surface of interest are provided. Such systems and methods may include taking ray traces to determine light contact with the surface of interest. Shadow maps may be generated. Power flux calculations may also be performed.

Abstract: The present invention provides a fusion protein, comprising: a) a ligand that stimulates cancer cell growth and corresponds to receptors overexpressed by cancer cells, or a screened peptide that is affinitive to or antagonist to cancer cell receptors, or a peptide that directly interacts with cancer cell surface; b) a superantigen that may lead to anti-cancer immune response. It also discloses expression vectors and host cells comprising this fusion protein, methods for preparing this fusion protein, and the application of this fusion protein to prepare therapeutic agents for cancer or immune disease treatment.